Skip to main content
    S

    Solventum Corp. (SOLV)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $88.65
    -0.43 (-0.48%)

    Market Cap: $15.14B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Solventum Corp. (SOLV) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Solventum (SOLV) trades at 12.6x trailing earnings and 1.9x sales. Its forward P/E is 12.9x. The median P/E across 11 similar companies is 21.2x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 2.3% lower over the next year.

    MultipleValue
    P/E (trailing)12.6x
    Forward P/E12.9x
    Price to sales1.9x
    Price to book3.2x
    EV/EBITDA21.1x
    PEG1.2

    As of Nov 17, 2026

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About SOLV

    What is SOLV's forward P/E ratio?

    Solventum has a forward P/E ratio of 12.9x.

    Is SOLV stock overvalued?

    GNG's valuation label for SOLV is Fairly valued. Its P/E of 12.6x compares with a median of 21.2x across 11 similar companies.

    What is SOLV's price to sales ratio?

    Solventum has a price to sales ratio of 1.9x.

    What is SOLV's PEG ratio?

    Solventum has a PEG ratio of 1.2.